#EarningsWithMC: ITC Ltd is slated to announce its #Q2FY22 later in the day. Here's what the experts expect π
https://www.moneycontrol.com/news/business/earnings/itc-q2-result-preview-pat-may-rise-up-to-12-yoy-say-analysts-7632161.html?utm_source=telegram&utm_medium=social
https://www.moneycontrol.com/news/business/earnings/itc-q2-result-preview-pat-may-rise-up-to-12-yoy-say-analysts-7632161.html?utm_source=telegram&utm_medium=social
Moneycontrol
ITC Q2 Result Preview: PAT May Rise Up To 12% YoY, Say Analysts
As per analysts, key factors to watch out for include the outlook on Hotels division, cigarette demand and price trends, adoption of newly-launched products, and performance of Agri and Packaging divisions.
#EarningsWithMC: #SBI today is expected to see significant growth in #Q2FY22 profit due to lower credit cost and provisions for bad loans.
Here's what analysts say π
https://www.moneycontrol.com/news/business/earnings/sbi-q2-preview-analysts-expect-significant-growth-in-profit-with-lower-credit-cost-easing-npa-pressure-7671291.html?utm_source=telegram&utm_medium=social
Here's what analysts say π
https://www.moneycontrol.com/news/business/earnings/sbi-q2-preview-analysts-expect-significant-growth-in-profit-with-lower-credit-cost-easing-npa-pressure-7671291.html?utm_source=telegram&utm_medium=social
Moneycontrol
SBI Q2 Preview | Analysts expect significant growth in profit with lower credit cost, easing NPA pressure
Overall, despite the situation on the ground, Kotak expects a solid positive commentary on SBI's retail/corporate loan book from an asset quality perspective.
#MCPro | Sun Pharma has posted another strong quarter #Q2FY22 on the specialty products front, despite the COVID wave in the US. Read β¬
https://www.moneycontrol.com/news/business/moneycontrol-research/sun-pharma-fully-valued-though-performance-impressive-7672911.html?utm_source=telegram&utm_medium=social
https://www.moneycontrol.com/news/business/moneycontrol-research/sun-pharma-fully-valued-though-performance-impressive-7672911.html?utm_source=telegram&utm_medium=social
Moneycontrol
Sun Pharma: Fully valued, though performance impressive
Sales of specialty products during the reporting quarter clocked $157 million against $148 million in Q1FY22 and $108 million in Q2FY21.
#ZeeEntertainment will hold its board meeting on November 11 to consider #Q2FY22 results, the company said in an exchange filing
https://www.moneycontrol.com/news/business/companies/zee-to-hold-board-meeting-to-consider-q2-fy22-results-on-november-11-7675081.html?utm_source=telegram&utm_medium=social
https://www.moneycontrol.com/news/business/companies/zee-to-hold-board-meeting-to-consider-q2-fy22-results-on-november-11-7675081.html?utm_source=telegram&utm_medium=social
Moneycontrol
Zee To Hold Board Meeting To Consider Q2 FY22 Results On November 11
On October 26, the company had said that it cancelled its October 27 board meeting due to lack of quorum.
Trent's investors are pleased with the company's #Q2FY22 results. Its standalone revenues have surpassed #Q2FY20 revenues, which was a pre-pandemic quarter.
Read more at:
https://www.moneycontrol.com/news/business/earnings/trents-investors-give-thumbs-up-to-september-quarter-results-7674721.html?utm_source=telegram&utm_medium=social
Read more at:
https://www.moneycontrol.com/news/business/earnings/trents-investors-give-thumbs-up-to-september-quarter-results-7674721.html?utm_source=telegram&utm_medium=social
Moneycontrol
Trentβs Investors Give Thumbs Up To September Quarter Results
Trent's investors are pleased with the company's Q2FY22 results. It's standalone revenues have surpassed Q2FY20 revenues, which was a pre-pandemic quarter.
#BuzzingStocks β‘οΈAlembic Pharmaceuticals share price fell over 4 % intraday to Rs 757 after the company reported a weak set of numbers for #Q2FY22:
https://www.moneycontrol.com/news/business/stocks/alembic-pharma-share-price-falls-4-on-weak-q2-usfda-observations-7705221.html?utm_source=telegram&utm_medium=social
https://www.moneycontrol.com/news/business/stocks/alembic-pharma-share-price-falls-4-on-weak-q2-usfda-observations-7705221.html?utm_source=telegram&utm_medium=social
Moneycontrol
Alembic Pharma Share Price Falls 4% On Weak Q2, USFDA Observations
The company reported 49.2 percent fall in its Q2 net profit at Rs 169.29 crore against Rs 333.37 crore and revenue was down 11.3% at Rs 1,292.32 crore versus Rs 1,457.10 crore, YoY.
Wonderla Holidays MD, Arun K Chittilappilly during the #Q2FY22 investor call said that this financial year there is no decision regarding starting new projects and that the focus is on business revival
https://www.moneycontrol.com/news/business/companies/no-decision-to-start-new-projects-in-fy22-focus-on-business-revival-says-wonderla-holidays-md-7708661.html?utm_source=telegram&utm_medium=social
https://www.moneycontrol.com/news/business/companies/no-decision-to-start-new-projects-in-fy22-focus-on-business-revival-says-wonderla-holidays-md-7708661.html?utm_source=telegram&utm_medium=social
Moneycontrol
No Decision To Start New Projects In FY22, Focus On Business Revival, Says Wonderla Holidays MD
Company will prefer to do their own projects which includes launching a park in Chennai for which Wonderla Holidays will be investing Rs 300 crore.
#EarningsWithMC: The #Q2 results season has reached its fag end now with all the mainstream companies having declared their results.
How did corporate India fare in #Q2FY22? π€ Gaurav Sharma finds out π»
https://www.moneycontrol.com/news/business/earnings/q2-results-review-how-corporate-india-fared-in-the-second-quarter-of-fy22-7733451.html?utm_source=telegram&utm_medium=social
How did corporate India fare in #Q2FY22? π€ Gaurav Sharma finds out π»
https://www.moneycontrol.com/news/business/earnings/q2-results-review-how-corporate-india-fared-in-the-second-quarter-of-fy22-7733451.html?utm_source=telegram&utm_medium=social
Moneycontrol
Q2 Results Review: How Corporate India Fared In The Second Quarter Of FY22
Going forward, market movements are likely to be determined more by global developments like spurt in inflation and a sooner-than-expected hike in interest rates by the central banks.
#DailyVoice π The real #GDP growth rate in #Q2FY22 is expected to be between 7.5% and 8%: Amit Pamnani of Swastika Investmart Ltd.
Read the full interview at π
https://www.moneycontrol.com/news/business/markets/daily-voice-real-gdp-growth-in-q2fy22-may-come-in-around-7-5-8-says-amit-pamnani-of-swastika-7737861.html?utm_source=telegram&utm_medium=social
Read the full interview at π
https://www.moneycontrol.com/news/business/markets/daily-voice-real-gdp-growth-in-q2fy22-may-come-in-around-7-5-8-says-amit-pamnani-of-swastika-7737861.html?utm_source=telegram&utm_medium=social
Moneycontrol
Daily Voice | Real GDP Growth In Q2FY22 May Come In Around 7.5-8%, Says Amit Pamnani Of Swastika
Talking about the recent IPOs, Amit Pamnani said it is a Nifty time for raising funds from primary markets as all categories of investors are aggressively investing in markets due to the lowest rates on FDs and bonds.
#DailyVoice π India's #Q2FY22 #GDP is expected to be in the 7-9% range: Sonam Srivastava, Co-founder, Wright Research.
Read at:
https://www.moneycontrol.com/news/business/markets/daily-voice-2022-too-will-be-robust-for-ipos-but-paytm-listing-is-a-wake-up-call-says-sonam-srivastava-of-wright-research-7743621.html?utm_source=telegram&utm_medium=social
Read at:
https://www.moneycontrol.com/news/business/markets/daily-voice-2022-too-will-be-robust-for-ipos-but-paytm-listing-is-a-wake-up-call-says-sonam-srivastava-of-wright-research-7743621.html?utm_source=telegram&utm_medium=social
Moneycontrol
Daily Voice | 2022 Too Will Be Robust For IPOs But Paytm Listing Is A Wake-up Call, Says Sonam Srivastava Of Wright Research
Indian economyβs long-term prospects are strong but the drawdown may extend. There is a view that India has not seen a 10 percent or more correction for a long time and its overdue, says Srivastava
Zee Entertainment reported 16% growth in #advertising revenue in the third quarter of FY22, up from Rs 1,089.3 crore in #Q2FY22 to Rs 1,260.8 crore in #Q3FY22, reports Maryam Farooqui.
Read
https://www.moneycontrol.com/news/business/companies/zee-sees-ad-revenue-reach-95-of-pre-covid-levels-but-uncertainty-looms-due-to-pandemic-8029391.html?utm_source=telegram&utm_medium=social
Read
https://www.moneycontrol.com/news/business/companies/zee-sees-ad-revenue-reach-95-of-pre-covid-levels-but-uncertainty-looms-due-to-pandemic-8029391.html?utm_source=telegram&utm_medium=social
Moneycontrol
Zee sees ad revenue reach 95% of pre-Covid levels but uncertainty looms due to pandemic
In the nine months of FY22, advertising revenue grew to Rs 3276.7 crore from Rs 2625.8 crore during the same period in FY21